TTFields
Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About Novocure
Founded in 2000 by Professor Yoram Palti, Novocure has developed a unique, physics-based cancer treatment platform that targets solid tumors with electric fields, offering a treatment option with a distinct side-effect profile. Its first commercial success came with FDA approvals for glioblastoma in 2011 and 2015, and it recently secured a landmark approval for pancreatic cancer in 2024. The company's strategy centers on broadening the clinical validation of TTFields across multiple cancer types through a robust late-stage clinical pipeline.
View full company profileAbout Novocure
Founded in 2000 by Professor Yoram Palti, Novocure has developed a unique, physics-based cancer treatment platform that targets solid tumors with electric fields, offering a treatment option with a distinct side-effect profile. Its first commercial success came with FDA approvals for glioblastoma in 2011 and 2015, and it recently secured a landmark approval for pancreatic cancer in 2024. The company's strategy centers on broadening the clinical validation of TTFields across multiple cancer types through a robust late-stage clinical pipeline.
View full company profileAbout Novocure
Founded in 2000 by Professor Yoram Palti, Novocure has developed a unique, physics-based cancer treatment platform that targets solid tumors with electric fields, offering a treatment option with a distinct side-effect profile. Its first commercial success came with FDA approvals for glioblastoma in 2011 and 2015, and it recently secured a landmark approval for pancreatic cancer in 2024. The company's strategy centers on broadening the clinical validation of TTFields across multiple cancer types through a robust late-stage clinical pipeline.
View full company profileAbout Novocure
Founded in 2000 by Professor Yoram Palti, Novocure has developed a unique, physics-based cancer treatment platform that targets solid tumors with electric fields, offering a treatment option with a distinct side-effect profile. Its first commercial success came with FDA approvals for glioblastoma in 2011 and 2015, and it recently secured a landmark approval for pancreatic cancer in 2024. The company's strategy centers on broadening the clinical validation of TTFields across multiple cancer types through a robust late-stage clinical pipeline.
View full company profileAbout Novocure
Founded in 2000 by Professor Yoram Palti, Novocure has developed a unique, physics-based cancer treatment platform that targets solid tumors with electric fields, offering a treatment option with a distinct side-effect profile. Its first commercial success came with FDA approvals for glioblastoma in 2011 and 2015, and it recently secured a landmark approval for pancreatic cancer in 2024. The company's strategy centers on broadening the clinical validation of TTFields across multiple cancer types through a robust late-stage clinical pipeline.
View full company profileAbout Novocure
Founded in 2000 by Professor Yoram Palti, Novocure has developed a unique, physics-based cancer treatment platform that targets solid tumors with electric fields, offering a treatment option with a distinct side-effect profile. Its first commercial success came with FDA approvals for glioblastoma in 2011 and 2015, and it recently secured a landmark approval for pancreatic cancer in 2024. The company's strategy centers on broadening the clinical validation of TTFields across multiple cancer types through a robust late-stage clinical pipeline.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| NBTXR3 + anti-PD1 | Nanobiotix | Phase 1 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1/2 |
| VAC2 | Lineage Cell Therapeutics | Phase 1 |
| TG6050 | Transgene SA | Preclinical |
| Monalizumab (IPH2201) | Innate Pharma | Phase 3 |
| Plinabulin | BeyondSpring | Phase 2/3 |
| PD1-Vaxx (IMU-201) | Imugene | Phase 1 |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |
| Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab) | Genprex | Phase 1/2 |
| ABD-3001 | Advanced Biodesign | Phase 1 |